|
|
Alnylam Pharmaceuticals
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: Alnylam product revs - Leqvio numbers NVS filed a 6-K report today with the numbers for Q4 on Leqvio. Sales were about $42M. They also had the following info in the report. New long-term data from the ORION-3 open-label study demonstrated effective and sustained reductions in LDL cholesterol over four years of treatment. At any time throughout the trial, approximately 80% of patients reached an LDL-C level of <70mg/dL. Data presented at AHA 2022 |
||||||||||||
|
|
return to message board, top of board |
